By Karen Manning, MBA, BSN, RN, Director, Business Solutions

CMS has finalized the CY 2027 Final Rule, largely confirming the direction set out in the proposed rule.
While the updates may look incremental on the surface, they send a clear signal: Star Ratings are continuing to move away from operational and administrative measures and toward clinical quality and outcomes.

For Medicare Advantage plans, the rule reshapes how Star Ratings performance is evaluated, rewarded, and sustained.

Measure	Status	Stars Year
Plan Makes Timely Decisions about Appeals (Part C)	Removed	2029
Reviewing Appeals Decisions (Part C)	Removed	2029
Special Needs Plan (SNP) Care Management (Part C)	Removed	2029
Call Center Interpreter and TTY (Part C + D)	Removed	2028
Complaints About the Health/Drug Plan (Part C + D)	Removed	2029
Medicare Plan Finder Price Accuracy (Part D)	Removed	2029
Diabetes Care – Eye Exam (Part C)	Retained	2029
Statin Therapy for Patients with CVD (Part C)	Removed	2028
Members Choosing to Leave the Plan (Part C + D)	Removed	2029
Customer Service (Part C)	Removed	2029
Rating of Health Care Quality (Part C)	Removed	2029
Depression Screening and Follow-Up (Part C)	Added	2029
Health Equity Index (HEI)	Not Implemented	2027

A Narrower, More Clinical Star Ratings Program

Beginning in Star Ratings year 2029 (with some changes effective earlier), CMS will remove 11 administrative and high-performance measures, retain one, add one new clinical measure, and postpone implementation of the Health Equity Index (HEI).

Key Star Ratings changes include:

• Removal of administrative and experience measures, including appeals processing, customer service, complaints, and plan disenrollment.
• Retention of Diabetes Care – Eye Exam (Part C), reinforcing the continued importance of core clinical quality within Stars.
• Addition of Depression Screening and Follow-Up (Part C), further shifting Star Ratings toward outcomes-based, clinically validated performance.
• No implementation of the Health Equity Index in 2027, extending the runway for plans to operationalize equity-focused data strategies before they are reflected in Stars.
• CMS estimates the net financial impact of these Star Ratings updates at $18.56B from 2027–2036, representing approximately 0.21% of total Medicare payments to private health plans over ten years.

The Star Ratings takeaway is straightforward: fewer administrative measures, less insulation from performance volatility, and a sharper focus on measurable clinical outcomes.

A Star Ratings Reality Check

The most important message in the Final Rule is not which measures were removed, but what CMS is now rewarding through Star Ratings.

As operational Stars measures roll off, performance increasingly depends on how effectively a plan can:

• Identify care gaps with precision
• Close those gaps consistently
• Demonstrate outcomes with confidence

This raises the bar for how plans support Star Ratings performance through clinical data.

CMS frames these changes as part of a broader effort to reduce reliance on administrative processes and elevate outcomes-based measurement. In Star Ratings terms, traditional strategies—manual chart chasing, lagging supplemental data, and fragmented vendor workflows—will not scale in a program where clinical credibility directly influences revenue.

Outcomes-Based Stars Raise the Data Standard

As Star Ratings tilt toward outcomes, plans need deeper, more timely visibility into what is happening in provider settings.

The Final Rule reinforces several Star Ratings imperatives:

• Electronic supplemental clinical data must be acquired and ingested at scale to support accurate, defensible Stars measurement.
• Payer-to-provider data exchange must be cleaner and more trustworthy, so providers can act on Stars gap lists with confidence.
• More continuous measurement enables earlier intervention, helping plans identify gaps sooner and close them before measurement windows close.

Outcomes-based Stars are unforgiving when clinical data arrives late, incomplete, or disconnected from provider workflows.

The Strategic Implication: Star Ratings Will Expose Fragmented Operating Models

One understated consequence of the Final Rule is what it means for long‑standing Star Ratings operating models.

As Stars refocus on outcomes, plans need more integrated approaches, not more point solutions.
Disconnected vendors managing data ingestion, quality measurement, analytics, and provider engagement in isolation make it harder to execute against an outcomes‑first Stars program.

CMS’ direction favors:

• Shared data foundations that support Stars end-to-end
• Streamlined workflows across quality, analytics, and provider engagement
• Fewer handoffs between systems during Stars measurement cycles

Plans that continue to layer new tools onto fragmented Stars processes risk trading administrative complexity for clinical blind spots.

How Abacus Supports Outcomes-Focused Star Ratings

At Abacus Insights, we see the CY 2027 Final Rule as validation of a direction many plans are already facing in their Star Ratings programs.

Our platform supports plans as they:

• Acquire and normalize electronic clinical data needed for Stars measurement
• Enable trusted payer-to-provider data exchange tied to care gap closure
• Monitor outcomes-focused Stars performance more continuously

As Star Ratings move away from administrative scoring and toward demonstrable clinical results, a strong data foundation separates reactive quality management from proactive Stars performance.

Bottom Line

The CY 2027 Final Rule signals that CMS expects Medicare Advantage plans to prove outcomes through Star Ratings rather than rely on administrative processes.

Plans that invest in clinically credible, outcomes-ready data strategies are better positioned to manage Star Ratings volatility and sustain performance over time. Fewer measures do not make Stars easier; they make execution more exposed and performance more consequential.

View our Stars Performance page or contact us for more information.